UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in its charter) |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On January 2, 2024, the Registrant’s Board of Directors appointed the following independent directors to serve as members of the audit, nominating and compensation committees.
| Committee | Chair | Members | ||
| Audit Committee | Mia Kuang Ching | Barry I. Regenstein & Timothy H. Safransky | ||
| Nominating Committee | Sammi Ean Seok Ang | Timothy H. Safransky & Mia Kuang Ching | ||
| Compensation Committee | Timothy H. Safransky | Mia Kuang Ching & Barry I. Regenstein |
The Board of Directors also approved, effective January 2, 2024, that each independent director will be paid $4,000 monthly for their service as a director of the Company.
The Board of Directors also elected Mr. Fnu Oudom as the Chairman of the Board.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: January 5, 2024 | BIMI International Medical Inc. | |
| By: | /s/ Tiewei Song | |
| Name: | Tiewei Song | |
| Title: | Chief Executive Officer | |
2
Cover |
Jan. 02, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jan. 02, 2024 |
| Entity File Number | 001-34890 |
| Entity Registrant Name | BIMI International Medical Inc. |
| Entity Central Index Key | 0001213660 |
| Entity Tax Identification Number | 02-0563302 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 725 5th Avenue |
| Entity Address, Address Line Two | 15th Floor |
| Entity Address, Address Line Three | 15-01 |
| Entity Address, City or Town | New York |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 10022 |
| City Area Code | 212 |
| Local Phone Number | 542 0028 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, $0.001 par value |
| Trading Symbol | BIMI |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
M-8?20$3;8T.P6BP^0"X99K>]9!:G